Comparing oral and transdermal estrogen therapy in women with Turner syndrome
Official title: Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome - A Randomized Trial
Run by University of Aarhus · NCT06570460 · Data updated 2026-11-12
This study is testing whether taking estrogen as a pill or through the skin is better for women with Turner syndrome in terms of their overall health and well-being.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 50 Years |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | University of Aarhus Academic / other |
| Locations | 1 site (Aarhus, Aarhus N) |
| Status | Recruiting |
| Started | November 29, 2021 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 26, 2024 |
| Trial ID | NCT06570460 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women aged 18-50 with a diagnosis of Turner syndrome who are already receiving estrogen treatment.
✕Probably not a fit
Patients with active systemic chronic diseases, known or suspected breast cancer, or those who are postmenopausal will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase IV, randomized controlled crossover trial investigates the long-term effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome. The study involves 50 participants with Turner syndrome aged 18-50, who will undergo a wash-out period before being randomized to receive either oral or transdermal ERT for six months, followed by a crossover to the alternate treatment for another six months. The trial aims to clarify various health risks associated with Turner syndrome and evaluate the efficacy of both ERT routes on endocrine, metabolic, cardiovascular, and thromboembolic factors.
Why it matters
Potential benefit: If successful, this study could provide insights into the most effective form of estrogen therapy for women with Turner syndrome, potentially improving their long-term health outcomes.
How similar studies have gone: While there is ongoing debate regarding the best method of estrogen administration in Turner syndrome, this specific comparative approach has not been extensively tested, making it a novel investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: For participants with TS: * Diagnosis of TS regardless of karyotype * Age 18-50 years * Already receiving estrogen treatment For healthy controls: * Female * Age 18-50 years * Previously healthy * Not receiving any medication * Not using any form of contraceptive pills * No mental or psychiatric disorders Exclusion criteria: * Active systemic chronic diseases * Known or suspected breast cancer * Known or suspected estradiol-dependent tumors (endometrial cancer or similar) * Untreated endometrial hyperplasia * Current or previous venous thromboembolism * Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more * Known hypersensitivity to the medications used * Pregnancy * Menopause (for the control group only)
Where it's running
-
Department of Endocrinology and Internal Medicine, Aarhus University Hospital
Aarhus, Aarhus N, Denmark Recruiting
Study contacts
- Principal investigator: Claus H Gravholt, Professor — Aarhus University Hospital
- Study coordinator: Camilla M Balle, Ph.d.-student
- Email: camibl@clin.au.dk
- Phone: 40769623
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing oral and transdermal estrogen treatment in women with Turner syndrome
This study is testing whether taking estrogen by mouth or through the skin works better for women with Turner syndrome.
-
Investigating the link between HIV infection and male hypogonadism
This study looks at how common low testosterone is in men with HIV compared to men without HIV to see what factors might be linked to it.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Inpegsomatropin vs Givopegsomatropin for short stature in girls with Turner syndrome
A 52-week, multicenter, randomized study tests whether Inpegsomatropin injections help prepubertal girls with Turner syndrome grow taller compared with a known treatment.
-
Adherence to a creatine-based nutritional supplement in estrogen-depleted women
This 12-week observational project will test how well estrogen-depleted women stick to taking a creatine-based nutritional supplement.
-
Men's experiences with ICSI and low sperm quality
This project will see if Danish men with low sperm quality who undergo ICSI have lower quality of life or low testosterone and how they experience interactions with health professionals.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.